ASPREE-D: Aspirin for the prevention of depression in the elderly

ASPREE investigators

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Background: Not only is depression associated with increased inflammation but inflammation is a risk factor for the genesis of depression. Many of the environmental risk factors for depression are transduced through inflammatory signaling. Anti-inflammatory agents show promise for the management of depression in preclinical, epidemiological, and early clinical studies. This opens the door to the potential for anti-inflammatory agents to treat and prevent depression. There are no evidence-based pharmacotherapies for depression prevention. Method: ASPREE-D, aspirin in the prevention of depression in the elderly, is a sub study of ASPREE, which explores the potential of aspirin to prevent a range of inflammation related disorders in the elderly. With a sample size of 19,114, and a duration of 5 years, this placebo controlled study will be one of the largest randomized controlled trials in psychiatry and will provide definitive evidence on the ability of aspirin to prevent depression. Results: This paper presents the rationale for the study and presents a summary of the study design. Conclusions: ASPREE-D may not only define novel therapy but will provide mechanistic proof of concept of the role of inflammation in depression.

Original languageEnglish (US)
Pages (from-to)1741-1748
Number of pages8
JournalInternational Psychogeriatrics
Issue number10
StatePublished - Oct 1 2016

Bibliographical note

Publisher Copyright:
© Copyright International Psychogeriatric Association 2016.


  • antidepressants
  • aspirin
  • biomarkers
  • depression
  • immunology
  • inflammation
  • prevention
  • risk


Dive into the research topics of 'ASPREE-D: Aspirin for the prevention of depression in the elderly'. Together they form a unique fingerprint.

Cite this